Aspen Neuroscience, Inc. (ASPE)

Aspen Neuroscience Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-66.64	-59.31	-53.46
Net Income Net Income Growth	-66.84	-62.06	-48.56

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	72.38	110.7	57.68
Total Debt Total Debt Growth	9.77	11.2	13.83
Net Cash (Debt) Net Cash Growth	62.61	99.5	43.85
Net Cash Growth	-	126.89%	-

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-56.73	-52.85	-44.16
Capital Expenditures CapEx Growth	-9.78	-9.69	-2.58
Free Cash Flow Free Cash Flow Growth	-66.51	-62.54	-46.75
Free Cash Flow Growth	-	-	-

Data Source: SEC filings Last updated: Dec 31, 2025

The financial data was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error